Originators query switching
Executive Summary
One interchangeable biosimilar should not be substituted for another in the US, and US Food and Drug Administration (FDA) guidance should reflect that, several biologics originators argued during an FDA public hearing on biologic competition and innovation. The same point was echoed by the originator-backed Alliance for Safe Biologic Medicines (ASBM).